COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Fürstenau, Moritz; Langerbeins, Petra; Silva, Nisha De; Fink, Anna Maria; Robrecht, Sandra; Tresckow, Julia von; Simon, Florian; Hohloch, Karin; Droogendijk, Jolanda; Klift, Marjolein van der; Spek, Ellen van der; Illmer, Thomas; Schöttker, Björn; Fischer, Kirsten; Wendtner, Clemens; Tausch, Eugen; Stilgenbauer, Stephan; Niemann, Carsten Utoft; Gregor, Michael; Kater, Arnon P.; Hallek, Michael; Eichhorst, Barbara

doi:10.1038/s41375-020-0941-7

Cited by 41 publications

(42 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, Fürstenau et al. [19] could show that the venetoclax-based treatment combined with chemoimmunotherapy, as first-line treatment, could not improve patient outcome and led to the increased rate of COVID-19 along with increased hospitalization rate. In Mato et al.…”

Section: Resultsmentioning

confidence: 99%

Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges

Roosta¹,

Behzadi²,

Askari³

et al. 2021

Leukemia Research Reports

View full text Add to dashboard Cite

A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interaction between CLL and COVID-19 remains a major challenge. Also, CLL patients have a lower rate of anti-SARS-CoV-2 IgG development. Evidences show the unacceptable therapeutic outcome in these patients. Although the CLL-COVID-19 occurrence is associated with adverse clinical consequences, no general and standard agreement has yet been presented for the management and treatment of this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges

Roosta¹,

Behzadi²,

Askari³

et al. 2021

Leukemia Research Reports

View full text Add to dashboard Cite

show abstract

“…Patients with hematological malignancies have usually long lasting immunodeficiency because of the malignancy itself but also because of anti-cancer treatments such as rituximab or hematopoietic stem-cell transplantations[ 16 ]. In a first report of COVID-19 in chronic lymphocytic leukemia (CLL) patients receiving venetoclax showed a substantial adaptive immune deficiency that might lead to an impairment of T-cell responses and more COVID-19 severity in infected CLL patients [ 17 ]. The cases of severe COVID-19 have also been reported in patients treated with anti-CD20 targeted therapy supporting the impact of B-cell depletion thereby the incapacity to produce neutralizing antibodies on COVID-19 course [ 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Mansi

Spehner

Daguindau

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

Background Cancer patients are considered as highly vulnerable to COVID-19 pandemic. However, delaying cancer specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients’ immune system responds to SARS-CoV-2 virus. Methods We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) on April 2020. The primary trial objective was to assess specific immune response’s intensity and diversity to SARS-CoV-2 for infected patients. Results In this study, we showed that cancer patients (28 solid tumors, 11 hematological malignancies) exposed to SARS-CoV-2 produced high rate of specific antibodies, as observed in patients without cancer history (n=29). However, our results highlight a lack in the generation of T-cell responses against CoV-N, M and S proteins from SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses was not hampered in cancer patients. Conclusion Given the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs.

show abstract

“…Recently, various investigations have demonstrated a positive correlation between BTK kinase activity and severity of COVID-19 infection (23)(24)(25)(26)(27)(28). In this context, administration of Acalabrutinib to 19 hospitalized patients with severe COVID-19 infection resulted in improvement in oxygenation in a majority of them (n=18), often within 1 to 3 days (23).…”

Section: Introductionmentioning

confidence: 99%

Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy

Rada¹,

Qusairy

Massip-Salcedo

et al. 2020

Molecular Cancer Research

View full text Add to dashboard Cite

The outbreak of the novel coronavirus disease 2019 has emerged as one of the biggest global health threats worldwide. As of October 2020, over 44 million confirmed cases and more than 1,160,000 deaths have been reported globally, and the toll is likely to be much higher before the pandemic is over. There are currently little therapeutic options available and new potential targets are intensively investigated. Recently, Bruton Tyrosine Kinase (BTK) has emerged as an interesting candidate. Elevated levels of BTK activity have been reported in blood monocytes from patients with severe COVID-19, compared to those from healthy volunteers. Importantly, various studies confirmed empirically that administration of BTK inhibitors (Acalabrutinib and Ibrutinib) decreased the duration of mechanical ventilation and mortality rate for hospitalized patients with severe COVID-19. Herein, we review the current information regarding the role of BTK in SARS-CoV-2 infections and the suitability of its inhibitors as drugs to treat COVID-19. Implications:The use of BTK inhibitors in the management of COVID-19 shows promise in reducing the severity of the immune response to the infection and thus mortality. However, BTK inhibition may be contributing in other ways to inhibit the effects of the virus and this will need to be carefully studied.

show abstract

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Cited by 41 publications

References 14 publications

Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges

Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy

Contact Info

Product

Resources

About